Table 1.
Distribution of Demographic and Clinical Characteristics According to Age Groups
| Variable | Age <85 Y (N=5907) | Age ≥85 Y (N=505) | P Value |
|---|---|---|---|
| Female sex | 2260 (38.3) | 286 (56.6) | <0.0001 |
| BMI >30 kg/m2 | 1690 (29.6) | 59 (12.2) | <0.0001 |
| Systemic hypertension | 4267 (72.6) | 391 (78.5) | 0.0044 |
| Congestive heart failure | 1543 (28.2) | 210 (44.7) | <0.0001 |
| Previous TIA/stroke/thromboembolism | 857 (14.7) | 104 (20.9) | 0.0002 |
| Vascular disease | 1204 (22.0) | 138 (29.5) | 0.0002 |
| Chronic renal failure | 722 (12.5) | 120 (24.3) | <0.0001 |
| Left atrial dilatation (diameter >40 mm) | 3443 (70.3) | 316 (77.3) | 0.0030 |
| Chronic obstructive pulmonary disease | 653 (11.2) | 74 (14.8) | 0.014 |
| Antithrombotic therapies | |||
| No therapy | 349 (5.9) | 35 (6.9) | 0.410 |
| Oral anticoagulant | 4917 (83.2) | 393 (77.8) | 0.019 |
| VKA | 4556 (77.3) | 362 (71.7) | 0.0055 |
| NOAC | 361 (6.1) | 31 (6.1) | 0.9804 |
| Antiplatelet only | 641 (10.9) | 77 (15.3) | 0.0026 |
| Oral anticoagulant plus antiplatelet | 662 (11.2) | 50 (9.9) | 0.3699 |
Values are given as n (%). BMI indicates body mass index; NOAC, non–vitamin K antagonist oral anticoagulant; TIA, transient ischemic attack; VKA, vitamin K antagonist.